BNP Paribas Asset Management
BEAM icon

BNP Paribas Asset Management’s Beam Therapeutics BEAM Stock Holding History

BNP Paribas Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.3K Buy
1,524
+372
+32% +$10.3K ﹤0.01% 1849
2025
Q4 		$32K Buy
1,152
+408
+55% +$10.4K ﹤0.01% 1799
2025
Q3 		$18K Hold
744
– – ﹤0.01% 1422
2025
Q2 		$13K Buy
+744
New +$13K ﹤0.01% 1662

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BNP Paribas Asset Management's BEAM Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Beam Therapeutics (BEAM) stake by 32% in Q1 2026, buying an estimated $10.3K and bringing the position to 1,524 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1849.

BNP Paribas Asset Management first reported a position in BEAM in Q2 2025 and has held it in 4 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • BNP Paribas Asset Management held 1,524 shares of Beam Therapeutics worth $36.3K as of Q1 2026.
  • BNP Paribas Asset Management bought 372 Beam Therapeutics shares in Q1 2026, an estimated $10.3K.
  • Beam Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1849 holding.
  • BNP Paribas Asset Management first reported a position in Beam Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.